NCT04617795已完成不适用
Evaluating the Safety and Effectiveness of the Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 8
- 主要终点
- Hyperglycemia
研究概览
简要总结
The study subjects will be separated into 2 groups, depending on their previous insulin therapy with approximately 50% of subjects from each group, continuous glucose monitoring (CGM) naive.
Group A will complete a 2-week Standard Therapy Phase followed by 8 weeks of Omnipod 5 system use.
Group B will complete a 2-week Standard Therapy Phase followed by 10 weeks of Omnipod 5 system use.
Group A and Group B will have an optional 6-month extension of Omnipod 5 system use
详细描述
Basal-Bolus - Group A (N=12)
- 2 weeks standard therapy - using multiple daily injections (MDI) and Dexcom G6 continuous glucose monitoring (CGM) , followed by:
- 4 weeks Omnipod 5 system use in Automated Mode with optional bolus, followed by:
- 4 weeks Omnipod 5 system use in Automated Mode with simplified bolus
- 6-month optional extension using Automated Mode
Basal - Group B (N=12)
-
2 weeks standard therapy - using basal injection only and Dexcom G6 continuous glucose monitoring (CGM) , followed by:
-
2 weeks Omnipod 5 system use in Manual Mode with Dexcom G6 continuous glucose monitoring (CGM) - with fixed basal rate, no bolus, followed by:
-
4 weeks Omnipod 5 system use in Automated Mode with optional bolus, followed by:
-
If % time in range 70-180 mg/dL during Automated Mode is ≤50%, 4 weeks Omnipod 5 system use in Automated Mode with simplified bolus, OR
-
If % time in range 70-180 mg/dL during Automated Mode is >50%, 4 weeks Omnipod 5 system use in Automated Mode with optional bolus
-
6-month optional extension using Automated Mode
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Device Feasibility
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age at time of consent 18-75 years
- •Diagnosed with type 2 diabetes on insulin therapy by injection: basal-bolus (12 subjects) or basal only (12 subjects) regimens
- •A1C 8.0-12.0%
- •Has not used an insulin pump within 3 months of screening
- •Willing to use only the following types of insulin during the study: Humalog, Novolog, Admelog or Apidra during the study
- •Maximum insulin dose of 200 units/day
- •Stable doses over the last 4 weeks of other glucose-lowering medications as determined by Investigator
- •Willing to wear the system continuously throughout the study
- •Deemed appropriate for pump therapy per investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities
- •Investigator has confidence that the subject has the cognitive ability and can successfully operate all study devices and can adhere to the protocol
- •Must be willing to use the Dexcom App on the Omnipod 5 PDM as the sole source of Dexcom data (except for the Dexcom Follow App) during Automated Mode
- •Subjects scoring ≥ 4 on the Clarke Questionnaire must agree to have an overnight companion, defined as someone who resides in the same home or building as the study subject and who can be available overnight
- •Able to read and speak English fluently
- •Willing and able to sign the Informed Consent Form (ICF)
排除标准
- •A medical condition, which in the opinion of the investigator, would put the subject at an unacceptable safety risk
- •Planned major surgery during the study
- •History of severe hypoglycemia in the past 6 months
- •History of diabetic ketoacidosis (DKA) in the past 6 months, unrelated to an intercurrent illness, infusion set failure or initial diagnosis
- •Diagnosed with a blood dyscrasia or bleeding disorder
- •Plans to receive blood transfusion over the course of the study
- •Currently diagnosed with anorexia nervosa or bulimia
- •Currently on hemodialysis
- •History of adrenal insufficiency
- •Has taken oral or injectable steroids within the past 8-weeks or plans to take oral or injectable steroids during the study
- •Unable to tolerate adhesive tape or has any unresolved skin condition in sensor or pump placement
- •Plans to use insulin other than U-100 insulin during the Omnipod 5 phase of the study
- •Cardiac disease with functional status New York Heart Association Class III or IV or current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the previous 12-months.
- •Pregnant or lactating, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD, or implant)
- •Participation in another clinical study using an investigational drug or device other than the Omnipod 5 in the preceding 30-days or intends to participate during the study period
- •Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator's clinical judgment
结局指标
主要结局
Hyperglycemia
时间窗: 8-10 weeks and after 6-month optional extension
Overall percentage of time ≥250 mg/dL during standard therapy phase and ALL phases of Automated Mode
Hypoglycemia
时间窗: 8-10 weeks and after 6-month optional extension
Overall percentage of time \<54 mg/dL during standard therapy phase and all phases of Automated Mode
次要结局
- Percent of Time in Range 70-180 mg/dL(Automated Mode use (8-10 weeks and after 6-month optional extension) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B)
- Percent of Time > 180 mg/dL(Automated Mode use (8-10 weeks and after 6-month optional extension) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B)
- Percent of Time ≥ 300 mg/dL(Automated Mode use (8-10 weeks and after 6-month optional extension) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B)
- Percent of Time < 70 mg/dL(Automated Mode use (8-10 weeks and after 6-month optional extension) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B)
- Standard Deviation(Automated Mode use (8-10 weeks and after 6-month optional extension) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B)
- Coefficient of Variation (of Glucose)(Automated Mode use (8-10 weeks and after 6-month optional extension) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B)
- Mean Glucose(Automated Mode use (8-10 weeks and after 6-month optional extension) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B)
- Total Daily Insulin (Units)(Automated Mode use (8-10 weeks and after 6-month optional extension) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B)
- Total Daily Insulin (Units/kg)(Automated Mode use (8-10 weeks and after 6-month optional extension) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B)
- Change in Hemoglobin A1c (HbA1c)(End of study (8-10 weeks) and during extension (21-23 weeks and 24-26 weeks) compared to baseline (Days 57, 147, and 237 (Group A) or Days 71, 161, and 251 (Group B) compared to Day -30)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
2 期
Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab MonotherapyParoxysmal Nocturnal HemoglobinuriaNCT04811716Regeneron Pharmaceuticals24
已完成
3 期
A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and OverTetanusNCT06120751CanSino Biologics Inc.1,000
已完成
4 期
A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00399724Sanofi7,376
已完成
3 期
A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard TreatmentHepatitis C, ChronicNCT00703118Tibotec BVBA663
已完成
1 期
A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and OverTetanusNCT06123663CanSino Biologics Inc.60